RNA logo

RNA
Avidity Biosciences Inc

1,625
Mkt Cap
$11.28B
Volume
5.41M
52W High
$73.06
52W Low
$21.51
PE Ratio
-17.49
RNA Fundamentals
Price
$72.75
Prev Close
$72.92
Open
$72.92
50D MA
$72.45
Beta
1.21
Avg. Volume
1.7M
EPS (Annual)
-$2.89
P/B
5.67
Rev/Employee
$27,869.56
$1,750.11
Loading...
Loading...
News
all
press releases
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders PR...
PR Newswire·1d ago
News Placeholder
More News
News Placeholder
Rhumbline Advisers Decreases Stake in Avidity Biosciences, Inc. $RNA
Rhumbline Advisers lowered its stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 9.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 158,071...
MarketBeat·2d ago
News Placeholder
Fiera Capital Corp Has $52.39 Million Position in Avidity Biosciences, Inc. $RNA
Fiera Capital Corp lifted its position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 53.8% during the 3rd quarter, according to its most recent filing with the Securities and...
MarketBeat·5d ago
News Placeholder
Avidity Biosciences, Inc. $RNA Shares Acquired by Envestnet Asset Management Inc.
Envestnet Asset Management Inc. lifted its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 173.2% during the third quarter, according to the company in its most recent...
MarketBeat·5d ago
News Placeholder
Aberdeen Group plc Buys 25,000 Shares of Avidity Biosciences, Inc. $RNA
Aberdeen Group plc increased its position in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 8.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·5d ago
News Placeholder
Readystate Asset Management LP Makes New Investment in Avidity Biosciences, Inc. $RNA
Readystate Asset Management LP bought a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange...
MarketBeat·6d ago
News Placeholder
Assetmark Inc. Buys 21,507 Shares of Avidity Biosciences, Inc. $RNA
Assetmark Inc. lifted its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 72.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The...
MarketBeat·6d ago
News Placeholder
Avidity Biosciences (RNA) to Release Earnings on Thursday
Avidity Biosciences (NASDAQ:RNA) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...
MarketBeat·6d ago
News Placeholder
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 The New England Journal of...
PR Newswire·6d ago
News Placeholder
Allianz Asset Management GmbH Invests $632,000 in Avidity Biosciences, Inc. $RNA
Allianz Asset Management GmbH acquired a new stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the...
MarketBeat·10d ago
<
1
2
...
>

Latest RNA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.